SigmaDrugs Ltd is a Budapest based biotech start-up company founded in 2015. We are dedicated to developing novel applications of Sigma-1 receptor agonists for the treatment of chronic fibrotic diseases including end-stage renal failure, idiopathic pulmonary fibrosis as well as fibrosis in the eye. Preclinical studies have been completed, the patent has been accepted in the US, Europe, Israel, China, and Japan. In parallel, SigmaDrugs Ltd is also developing a patented preservation solution for organ transplantation which promotes protection of the graft, thus alleviating donor organ shortage and facilitating improved transplantation outcomes.